Medical Science Liaison Roles: Enigma and Dilemma
Author: Jane Chin, Ph.D., President, Medical Science Liaison Institute, LLC
After many hundreds of millions of penalty dollars from questionable sales and marketing practices, are pharmaceutical companies finally doing the “right” thing, at least where MSL roles are concerned? Are MSL directors trying? And are they getting more support from upper management?
Topics covered include:
- Flash from the Past: The Wishlist/Checklist for MSL Program ROI
- Substance behind the Symbol
- Bottom-line: Whose Pocketbooks?
- Clinical Research
- Educational Grants
- A Matter of Culture and Self Examination
Order this article and learn more … $29.95
(Pay online by credit card. 6-page PDF file delivered to you by email, usually within a few minutes)
Key Opinion Leaders, Medical Science Liaisons, & CME
A New Addition to the Pharma Marketing News Archives!
It’s a new era for pharmaceutical company support of physician education. New guidelines and regulations from various governmental and non-governmental regulatory bodies have come into play during the past few years. The second event defining this new era was the withdrawal of Vioxx from the market in 2004 and the subsequent re-emergence of the importance of physicians as “learned intermediaries.”
More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals.
This Special Supplement to Pharma Markeing News is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process.
Order and pay for this Special Supplement now using your credit card
PDF file delivered to you by email (usually within minutes of placing your order):
If you wish to be pay by check or credit card off-line, please use:
Printable Order Form